Adaptation of ACMG/AMP guidelines for clinical classification of BMPR2 variants in Pulmonary Arterial Hypertension resolves variants of unclear pathogenicity in ClinVar

Competing Interest Statement

CAE received honoraria for lectures and presentations from OMT and MSD, consulting fees from MSD. CAE is co-inventor of the issued European patent: Gene panel specific for pulmonary hypertension and its uses (EP3507380). CAE works at a laboratory that performs fee for service testing in genes that have been specified by the ClinGen PH-VCEP. FC works at a French healthcare hospital (Pitie-Salpetriere Hospital in Paris) laboratory which performs non-commercial fee for service testing in BMPR2 and other PAH genes. DD works at a Dutch healthcare hospital laboratory which performs non-commercial fee for service testing in BMPR2 and other PAH genes. ME worked at a French healthcare hospital laboratory which performs non-commercial fee for service testing in BMPR2 and other PAH genes. DM works for GeneDx, a laboratory that performs fee for service genetic testing. WKC serves on the Board of Directors of Prime Medicine. GMV was a graduate student at the time the study was performed, but is now employed by Tempus, a fee for service genetic testing company. MAA, SB, KMD, and GMV received funding from the NIH. All other authors declare no conflict of interest.

Funding Statement

This work was funded in part by NIH grant R35HL140019 (MAA, SB and KMD) and Diversity Supplement R35HL140019-S1 (GMV).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes